<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03789734</url>
  </required_header>
  <id_info>
    <org_study_id>BLS-M22-101</org_study_id>
    <nct_id>NCT03789734</nct_id>
  </id_info>
  <brief_title>Safety Study of BLS-M22 in Healthy Volunteers</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo-controlled and Dose-escalation Phase I Clinical Trial to Evaluate Safety of BLS-M22 Following Single/Multiple Oral Administration in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLeaders Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLeaders Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BLS-M22 is being developed as an anti-myotatin agent for the treatment of Duchenne Muscular
      Dystrophy (Muscular Dystrophy). A total of 37 subjects participated in this study to confirm
      the safety of BLS-M22.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a dose Block-randomized, Double-blind, Placebo-controlled and Dose-escalation
      Phase I Clinical Trial to Evaluate Safety of BLS-M22.

      The single ascending dose group participated in 9 patients in each group(500mg, 1,000mg,
      2000mg/BLS-M22 or Placebo(n=7:2)). The multiple ascending dose group participated in 10
      patients(determined dose in SAD/BLS-M22 or Placebo(n=8:2)).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 4-5 weeks</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>From 0 hours to 24 hours</time_frame>
    <description>Evaluation of the pharmacokinetic properties after administration of BLS-M22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity(Myostatin specific IgG level in serum)</measure>
    <time_frame>up to 4-5 weeks</time_frame>
    <description>Evaluation of the immunogenicity after administration of BLS-M22</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in muscle mass after Administration</measure>
    <time_frame>up to 4-5 weeks</time_frame>
    <description>Evaluation of the efficacy after Administraion of BLS-M22</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <arm_group>
    <arm_group_label>BLS-M22 or Placebo 500mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose (SAD): BLS-M22 500mg or Placebo 500mg (n=9; BLS-M22=7, Placebe=2) Oral Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BLS-M22 or Placebo 1,000mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose (SAD): BLS-M22 1,000mg or Placebo 1,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BLS-M22 or Placebo 2,000mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose (SAD): BLS-M22 2,000mg or Placebo 2,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Ascending Dose (MAD): BLS-M22 2,000mg or Placebo 2,000mg(n=10; BLS-M22=8 or Placebo=2) Oral Administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BLS-M22</intervention_name>
    <description>BLS-M22 250mg/capsule</description>
    <arm_group_label>BLS-M22 or Placebo 1,000mg group</arm_group_label>
    <arm_group_label>BLS-M22 or Placebo 2,000mg group</arm_group_label>
    <arm_group_label>BLS-M22 or Placebo 500mg group</arm_group_label>
    <arm_group_label>Multiple Ascending Dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>BLS-M22 placebo 250mg/capsule</description>
    <arm_group_label>BLS-M22 or Placebo 1,000mg group</arm_group_label>
    <arm_group_label>BLS-M22 or Placebo 2,000mg group</arm_group_label>
    <arm_group_label>BLS-M22 or Placebo 500mg group</arm_group_label>
    <arm_group_label>Multiple Ascending Dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects between 19-55 years of age

          2. BMI: 19~28kg/m2(male), 18~25kg/m2(female) at screening test

          3. Able to provide consent to participate and having signed an Informed Consent Form
             (ICF)

          4. The subjects can obey the demands of the scheme

        Exclusion Criteria:

          1. Subject has a clinically significant disease or history of liver, kidney,
             cardiovascular system, endocrine system, musculoskeletal system, digestive system,
             respiratory system, neuropsychiatry, bloodâˆ™tumor system.

          2. Hypersensitive to the lactobacillus-containing food (such as yogurt) and the
             lactobacillus preparation and the investigational drug

          3. Subject has received a investigational drug or a bioequivalence study drug within 90
             days of the randomization

          4. Subject has received steroids or other immunosuppressive drugs within 30 days of
             randomization

          5. Positive serum test results for hepatitis C virus, hepatitis B virus, HIV or syphilis

          6. Those who do not use of a medically acceptable method of contraception during the
             trial, or who plan to provide sperm

          7. Pregnant women

          8. Subject has genetic problems such as galactose intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption

          9. Subject has abnormal clinical laboratory test results

         10. Any other ineligible condition at the discretion of the investigator that would be
             ineligible to participate the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Hyung Lee</last_name>
    <role>Study Director</role>
    <affiliation>BioLeaders corp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae Hyung Lee</last_name>
    <phone>+82312809622</phone>
    <phone_ext>+82312809646</phone_ext>
    <email>jhlee@bioleaders.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bioleaders corp</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Yongin-si</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Hyung Lee</last_name>
      <phone>+82-31-280-9622</phone>
      <email>jhlee@bioleaders.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2018</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

